Venlafaxine與Fluoxetine治療重鬱症之單盲隨機臨床試驗

A Single-Blind and Randomized Trial of Venlafaxine and Fluoxetine for the Treatment of Major Depression

廖士程(Shih-Cheng Liao) ； 李明濱(Ming-Been Lee) ； 吳佳璇(Chia-Hsuan Wu) ； 陳映燁(Ying-Yeh Chen) ； 曾美智(Mei-Chih Tseng) ； 李宇宙(Yue-Joe Lee)

《台灣醫學》 7卷1期 (2003/01) Pp. 48-59

https://doi.org/10.6320/FJM.2003.7(1).06

摘要

This single-blind and randomized trial aims to compare the clinical efficacy and safety of venlafaxine and fluoxetine in the treatment of major depression. All patients included in the study met the Diagnostic and Statistic Manual of Mental Disorder, 4th edition (DSM-IV) criteria for a major depressive episode and presented with a total Hamilton Depression Rating Scale (HAM-D) score over 18 on the 21-item scale. Clinical efficacy was evaluated by 21-item HAM-D, Brief Symptom Rating Scale (BSRS) and Clinical Global Impression (CGI) weekly in the first four weeks and finally in the sixth week. A total of 63 patients who met the inclusion criteria were recruited in this study. In comparison of 31 venlafaxine and 32 fluoxetine treated patients, there was no significant difference in the scores of HAM-D and BSRS over the whole six-week study periods. The improvement based on CGI score at the fourth-week assessment was significantly higher in the patients treated by venlafaxine. There were no significant differences in the side effect profile except that the frequencies of dizziness were higher in the patients treated by venlafaxine in the first-week evaluation. This study revealed comparable clinical efficacy and safety of venlafaxine and fluoxetine in the treatment of major depression.

關鍵字

重鬱症 ； 臨床試驗 ； 選擇性血清素再吸收抑制藥 ； 選擇性新腎上腺素及血清素再吸收抑制藥

並列摘要

This single-blind and randomized trial aims to compare the clinical efficacy and safety of venlafaxine and fluoxetine in the treatment of major depression. All patients included in the study met the Diagnostic and Statistic Manual of Mental Disorder, 4th edition (DSM-IV) criteria for a major depressive episode and presented with a total Hamilton Depression Rating Scale (HAM-D) score over 18 on the 21-item scale. Clinical efficacy was evaluated by 21-item HAM-D, Brief Symptom Rating Scale (BSRS) and Clinical Global Impression (CGI) weekly in the first four weeks and finally in the sixth week. A total of 63 patients who met the inclusion criteria were recruited in this study. In comparison of 31 venlafaxine and 32 fluoxetine treated patients, there was no significant difference in the scores of HAM-D and BSRS over the whole six-week study periods. The improvement based on CGI score at the fourth-week assessment was significantly higher in the patients treated by venlafaxine. There were no significant differences in the side effect profile except that the frequencies of dizziness were higher in the patients treated by venlafaxine in the first-week evaluation. This study revealed comparable clinical efficacy and safety of venlafaxine and fluoxetine in the treatment of major depression.

並列關鍵字

major depression ； clinical trial ； selective serotonin reuptake inhibitor ； SSRI ； selective nor-epinephrine and serotonin reuptake inhibitor ； SNRI